December 13, 2016
Short: Active Biotech completes issuing rights, share capital up by €2,7M
The results of Active Biotech’s rights issue show that 6,643,426 shares, which is about 96 percent of the shares offered,…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
December 13, 2016
Type 2 diabetes gets new treatment in U.S., FDA OKs Boehringer’s Synjardy XR
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Synjardy XR tablets for adults with type 2 diabetes.…
December 12, 2016
Bayer and Versant Ventures to launch BlueRock Therapeutics
Bayer AG and Versant Ventures have announced the launch of BlueRock Therapeutics, a next-generation regenerative medicine company that plans to…
December 12, 2016
Novartis’s Monaleesa study show PFS in breast cancer treatment
Novartis has announced additional analyses from the Phase III MONALEESA-2 study that show LEE011 (ribociclib) plus letrozole significantly prolonged progression-free…
December 12, 2016
Achaogen passes US and European hurdles to market its plazomicin antibiotic
Achaogen’s multi-drug resistant (MDR) gram-negative product antibiotic candidate, plazomicin, met the objective for the U.S. Food and Drug Administration (FDA)…
December 12, 2016
Alvogen’s flu capsules alternative for Tamiflu
Alvogen on Monday launched the first flu capsules, generic equivalent to Roche’s Tamiflu (oseltamivir phosphate) capsules in the United States.
December 12, 2016
Ipsen science boss, R&D Vice President Claude Bertrand leaves
French drugmaker Ipsen said on Monday that Claude Bertrand, Executive Vice President, R&D, Chief Scientific Officer, will step down in January…
December 12, 2016
Eli Lilly and AstraZeneca join forces to fight Alzheimer’s disease
Eli Lilly and AstraZeneca have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which…
December 12, 2016
Short: Sycomore Asset Management’s share of Biocartis trigers transparency act
Biocartis Group NV said on Monday, in accordance with the Belgian Transparency Act, that Sycomore Asset Management now holds 3.01% of the…
December 12, 2016
Mereo balance sheet strong, sufficient funds for clinical tests
Mereo BioPharma Group, a clinical stage, UK-based biopharmaceutical company focused on rare diseases, is looking to strengthen its rare and specialty disease…